Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.41 |
| ▸ | CDC25A | P30304 | 1/20 | 0.41 |
| ▸ | CDC25B | P30305 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14734012 | 0.82 | HSD17B10 (0.53) | HSD17B10KMT2AALDH1A1POLBPKM | |
| SCHEMBL7620846 | 0.79 | KMT2A (0.48) | HSD17B10KMT2AALDH1A1POLBPKM | |
| SCHEMBL16846614 | 0.76 | PTGS2 (0.49) | ALDH1A1LMNASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1645197 | 0.75 | PTGS2 (0.49) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3842830 | 0.75 | SLC6A2 (0.46) | HSD17B10ALDH1A1POLBALOX15HTT | |
| SCHEMBL23409813 | 0.74 | ALDH1A1 (0.51) | HSD17B10KMT2AALDH1A1POLBPKM | |
| Ammonia Solution, Strong SCHEMBL27828064 | 0.74 | PKM (0.48) | HSD17B10KMT2AALDH1A1POLBPKM | |
| SCHEMBL3864880 | 0.74 | HSD17B10 (0.47) | HSD17B10KMT2AALDH1A1POLBPKM | |
| SCHEMBL1263353 | 0.73 | ALDH1A1 (0.54) | HSD17B10KMT2AALDH1A1POLBPKM | |
| Hydrochloric Acid SCHEMBL7362813 | 0.73 | AOC3 (0.46) | HSD17B10ALDH1A1POLBALOX15HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2271624-B9 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2014-11-12 | — | — | EP | disclosed |
| EP-2271624-B1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2014-05-21 | — | — | EP | disclosed |
| US-8481569-B2 | Iminopyridine derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-09 | — | — | US | disclosed |
| CN-102066327-B | Iminopyridine derivatives and use thereof | TAKEDA PHARMACEUTICAL | 2013-05-29 | — | — | CN | disclosed |
| US-7985863-B2 | Iminopyridine derivatives and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-26 | — | — | US | disclosed |
| US-7985862-B2 | Iminopyridine derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-26 | — | — | US | disclosed |
| US-7982044-B2 | Iminopyridine derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-19 | — | — | US | disclosed |
| US-20110124874-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| US-20110124875-A1 | IMINOPYRIDINE DERIVATIVES AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| US-20110124876-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| CN-102066327-A | Iminopyridine derivatives and use thereof | TAKEDA PHARMACEUTICAL | 2011-05-18 | — | — | CN | disclosed |
| US-20110039846-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-17 | — | — | US | disclosed |
| US-20110034464-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2271624-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-01-12 | — | — | EP | disclosed |
| US-20090270393-A1 | Iminopyridine Derivatives and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| WO-2009131245-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034464-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | ADRA1D, ADRB1, ADRB2 | HSD17B10 3225/4885KMT2A 2082/4885ALDH1A1 33/4885 |
| US-20110124876-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | ADRA1D, ADRB1, ADRB2 | HSD17B10 3225/4885KMT2A 2082/4885ALDH1A1 33/4885 |
| US-20110124875-A1 | IMINOPYRIDINE DERIVATIVES AND USES THEREOF | ADRA1D, ADRB1, ADRB2 | HSD17B10 3182/4885KMT2A 2344/4885ALDH1A1 33/4885 |
| US-20110124874-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | ADRA1D, ADRB1, ADRB2 | HSD17B10 3225/4885KMT2A 2082/4885ALDH1A1 33/4885 |
| US-20110039846-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | ADRA1D, ADRB1, ADRB2 | HSD17B10 3225/4885KMT2A 2082/4885ALDH1A1 33/4885 |
| US-20090270393-A1 | Iminopyridine Derivatives and Use Thereof | ADRA1D, ADRB1, ADRB2 | HSD17B10 3225/4885KMT2A 2082/4885ALDH1A1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.